Gyre Therapeutics Inc（GYRE）の財務GYREGyre Therapeutics Inc

Gyre Therapeutics, Inc. (GYRE) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is ETUARY, accounting for 90.6% of total sales, equivalent to $27.69M. Other significant revenue streams include Etorel and Contiva. Understanding this composition is critical for investors evaluating how GYRE navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, Gyre Therapeutics, Inc. maintains a gross margin of 92.41%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -47.62%, while the net margin is -49.03%. These profitability ratios, combined with a Return on Equity (ROE) of -19.91%, provide a clear picture of how effectively GYRE converts its operational activities into shareholder value.

In the context of the broader market, GYRE competes directly with industry leaders such as CTMX and PHAR. With a market capitalization of $698.76M, it holds a significant position in the sector. When comparing efficiency, GYRE's gross margin of 92.41% stands against CTMX's 100.00% and PHAR's N/A. Such benchmarking helps identify whether Gyre Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

Gyre Therapeutics has shown significant revenue growth, reporting $37.2 million in Q4 2026, a 33.5% increase year-over-year, but has also faced widening losses, with a net loss of $11.66 million in Q2 2026, reflecting challenges in profitability.